Connect with us

Hi, what are you looking for?

Health

Vaccines equally effective against B.1.617.2 variant after 2 doses: UK Study

Samples collected in test tubes in a laboratory. Photo: Ahmad Ardity/Pixabay

London, May 23 (MNN) Vaccine effectiveness against symptomatic disease from the B.1.617.2 variant (first detected in India) is similar after two doses compared to the B.1.1.7 (Kent) variant dominant in the UK, the Public Health England said.

It said that a PHE study found that for the period from April 5 to May 16:

• the Pfizer-BioNTech vaccine was 88 per cent effective against symptomatic disease from the B.1.617.2 variant 2 weeks after the second dose, compared to 93 per cent effectiveness against the B.1.1.7 variant.

• 2 doses of the AstraZeneca vaccine were 60 per cent effective against symptomatic disease from the B.1.617.2 variant compared to 66 per cent effectiveness against the B.1.1.7 variant.

• both vaccines were 33 per cent effective against symptomatic disease from B.1.617.2, three weeks after the first dose compared to around 50 per cent effectiveness against the B.1.1.7 variant.

The analysis included data for all age groups from April 5 to cover the period since the B.1.617.2 variant emerged.

It included 1,054 people confirmed as having the B.1.617.2 variant through genomic sequencing, including participants of several ethnicities.

Data published on May 20 for vaccine effectiveness covered the period since December for those aged over 65.

The difference in effectiveness between the vaccines after two doses may be explained by the fact that rollout of second doses of AstraZeneca was later than for the Pfizer-BioNTech vaccine, and other data on antibody profiles show it takes longer to reach maximum effectiveness with the AstraZeneca vaccine.

As with other variants, even higher levels of effectiveness are expected against hospitalisation and death.

There are currently insufficient cases and follow-up periods to estimate vaccine effectiveness against severe outcomes from the B.1.617.2 variant. PHE will continue to evaluate this over the coming weeks.

Health and Social Care Secretary Matt Hancock said: “This new evidence is groundbreaking – and proves just how valuable our COVID-19 vaccination programme is in protecting the people.

“We can now be confident that over 20 million people – more than 1 in 3 – have significant protection against this new variant, and that number is growing by the hundreds of thousands every single day as more and more people get that vital second dose. I want to thank the scientists and clinicians who have been working around the clock to produce this research.

“It’s clear how important the second dose is to secure the strongest possible protection against COVID-19 and its variants – and I urge everyone to book in their jab when offered.”

Dr Mary Ramsay, Head of Immunisation at PHE, said: “This study provides reassurance that two doses of either vaccine offer high levels of protection against symptomatic disease from the B.1.617.2 variant.

“We expect the vaccines to be even more effective at preventing hospitalisation and death, so it is vital to get both doses to gain maximum protection against all existing and emerging variants.”

Minister for COVID-19 Vaccine Deployment Nadhim Zahawi said: “Almost every day we get more and more encouraging evidence about the difference our COVID-19 vaccines are making to people’s lives – with 13,000 lives saved and 39,100 hospitalisations prevented overall.

“The data is astounding and a true reflection of just how important it is to get both your jabs when offered.”

Separate PHE analysis indicates that the COVID-19 vaccination programme has so far prevented 13,000 deaths and around 39,100 hospitalisations in older people in England, up to May 9.

You May Also Like

Religion

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Health

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Health

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.

Health

Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt.